Cargando…

Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing

BACKGROUND: Over 100 genes have been implicated in the aetiology of amyotrophic lateral sclerosis (ALS). A detailed understanding of their independent and cumulative contributions to disease burden may help guide various clinical and research efforts. METHODS: Using targeted high-throughput sequenci...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenna, Kevin P, McLaughlin, Russell L, Byrne, Susan, Elamin, Marwa, Heverin, Mark, Kenny, Elaine M, Cormican, Paul, Morris, Derek W, Donaghy, Colette G, Bradley, Daniel G, Hardiman, Orla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812897/
https://www.ncbi.nlm.nih.gov/pubmed/23881933
http://dx.doi.org/10.1136/jmedgenet-2013-101795
_version_ 1782289019087880192
author Kenna, Kevin P
McLaughlin, Russell L
Byrne, Susan
Elamin, Marwa
Heverin, Mark
Kenny, Elaine M
Cormican, Paul
Morris, Derek W
Donaghy, Colette G
Bradley, Daniel G
Hardiman, Orla
author_facet Kenna, Kevin P
McLaughlin, Russell L
Byrne, Susan
Elamin, Marwa
Heverin, Mark
Kenny, Elaine M
Cormican, Paul
Morris, Derek W
Donaghy, Colette G
Bradley, Daniel G
Hardiman, Orla
author_sort Kenna, Kevin P
collection PubMed
description BACKGROUND: Over 100 genes have been implicated in the aetiology of amyotrophic lateral sclerosis (ALS). A detailed understanding of their independent and cumulative contributions to disease burden may help guide various clinical and research efforts. METHODS: Using targeted high-throughput sequencing, we characterised the variation of 10 Mendelian and 23 low penetrance/tentative ALS genes within a population-based cohort of 444 Irish ALS cases (50 fALS, 394 sALS) and 311 age-matched and geographically matched controls. RESULTS: Known or potential high-penetrance ALS variants were identified within 17.1% of patients (38% of fALS, 14.5% of sALS). 12.8% carried variants of Mendelian disease genes (C9orf72 8.78%; SETX 2.48%; ALS2 1.58%; FUS 0.45%; TARDBP 0.45%; OPTN 0.23%; VCP 0.23%. ANG, SOD1, VAPB 0%), 4.7% carried variants of low penetrance/tentative ALS genes and 9.7% (30% of fALS, 7.1% of sALS) carried previously described ALS variants (C9orf72 8.78%; FUS 0.45%; TARDBP 0.45%). 1.6% of patients carried multiple known/potential disease variants, including all identified carriers of an established ALS variant (p<0.01); TARDBP:c.859G>A(p.[G287S]) (n=2/2 sALS). Comparison of our results with those from studies of other European populations revealed significant differences in the spectrum of disease variation (p=1.7×10(−4)). CONCLUSIONS: Up to 17% of Irish ALS cases may carry high-penetrance variants within the investigated genes. However, the precise nature of genetic susceptibility differs significantly from that reported within other European populations. Certain variants may not cause disease in isolation and concomitant analysis of disease genes may prove highly important.
format Online
Article
Text
id pubmed-3812897
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-38128972013-10-31 Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing Kenna, Kevin P McLaughlin, Russell L Byrne, Susan Elamin, Marwa Heverin, Mark Kenny, Elaine M Cormican, Paul Morris, Derek W Donaghy, Colette G Bradley, Daniel G Hardiman, Orla J Med Genet Screening BACKGROUND: Over 100 genes have been implicated in the aetiology of amyotrophic lateral sclerosis (ALS). A detailed understanding of their independent and cumulative contributions to disease burden may help guide various clinical and research efforts. METHODS: Using targeted high-throughput sequencing, we characterised the variation of 10 Mendelian and 23 low penetrance/tentative ALS genes within a population-based cohort of 444 Irish ALS cases (50 fALS, 394 sALS) and 311 age-matched and geographically matched controls. RESULTS: Known or potential high-penetrance ALS variants were identified within 17.1% of patients (38% of fALS, 14.5% of sALS). 12.8% carried variants of Mendelian disease genes (C9orf72 8.78%; SETX 2.48%; ALS2 1.58%; FUS 0.45%; TARDBP 0.45%; OPTN 0.23%; VCP 0.23%. ANG, SOD1, VAPB 0%), 4.7% carried variants of low penetrance/tentative ALS genes and 9.7% (30% of fALS, 7.1% of sALS) carried previously described ALS variants (C9orf72 8.78%; FUS 0.45%; TARDBP 0.45%). 1.6% of patients carried multiple known/potential disease variants, including all identified carriers of an established ALS variant (p<0.01); TARDBP:c.859G>A(p.[G287S]) (n=2/2 sALS). Comparison of our results with those from studies of other European populations revealed significant differences in the spectrum of disease variation (p=1.7×10(−4)). CONCLUSIONS: Up to 17% of Irish ALS cases may carry high-penetrance variants within the investigated genes. However, the precise nature of genetic susceptibility differs significantly from that reported within other European populations. Certain variants may not cause disease in isolation and concomitant analysis of disease genes may prove highly important. BMJ Publishing Group 2013-11 2013-07-23 /pmc/articles/PMC3812897/ /pubmed/23881933 http://dx.doi.org/10.1136/jmedgenet-2013-101795 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Screening
Kenna, Kevin P
McLaughlin, Russell L
Byrne, Susan
Elamin, Marwa
Heverin, Mark
Kenny, Elaine M
Cormican, Paul
Morris, Derek W
Donaghy, Colette G
Bradley, Daniel G
Hardiman, Orla
Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing
title Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing
title_full Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing
title_fullStr Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing
title_full_unstemmed Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing
title_short Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing
title_sort delineating the genetic heterogeneity of als using targeted high-throughput sequencing
topic Screening
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812897/
https://www.ncbi.nlm.nih.gov/pubmed/23881933
http://dx.doi.org/10.1136/jmedgenet-2013-101795
work_keys_str_mv AT kennakevinp delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing
AT mclaughlinrusselll delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing
AT byrnesusan delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing
AT elaminmarwa delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing
AT heverinmark delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing
AT kennyelainem delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing
AT cormicanpaul delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing
AT morrisderekw delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing
AT donaghycoletteg delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing
AT bradleydanielg delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing
AT hardimanorla delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing